![\"A](\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2025\/12\/b1c75604623e91c9_800x800ar.jpeg\")
<\/p>\n
\n
\n
\n
\n
<\/p>\n
M\u00f6lndal, Sweden \u2014 December 15, 2025 \u2014 Amferia, a Swedish medtech company developing next-generation antimicrobial wound-care solutions, today announced the close of an oversubscribed \u20ac3.5 million investment round. <\/p>\n
\u00a0<\/p>\n
The new funding\u2014led by both existing shareholders and several new investors prominent in global wound care\u2014will accelerate clinical development in human health, scale Amferia\u2019s growing animal-health business, and support commercialization of new products based on its proprietary antimicrobial peptide (AMP) hydrogel platform.<\/p>\n
\u00a0<\/p>\n
This investment follows a milestone year in which Amferia introduced Europe\u2019s first veterinary wound dressing using antimicrobial peptides, launched in collaboration with leading animal-health partners, and advanced its U.S. regulatory pathway for human wound care.<\/p>\n
\u00a0<\/p>\n
Fueling Growth Across Human and Veterinary Medicine<\/p>\n
\u00a0<\/p>\n
According to Amferia CEO and co-founder Anand Rajasekharan, the new financing will help the company advance clinical development toward CE marking and FDA clearance for human health applications in Europe and the United States, as well as expand Amferia\u2019s animal-health footprint in Europe, where the company has already secured commercial agreements with Orkla Wound Care AB and Biokema SA.<\/p>\n
\u201cThis funding will allow us to continue battling antibiotic-resistant bacteria and speed wound recovery in both human and animal patients,\u201d Rajasekharan said. <\/p>\n
\u00a0<\/p>\n
\u201cAmferia aims to broaden the new tools we offer clinicians to fight infection and reduce unnecessary antibiotic use. We hope to scale manufacturing and commercialization of our anti-microbial wound-care solution pipeline and broaden the platform to include applications such as surgical materials, implant sterilization, and deep-wound sprays.\u201d<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
The Race to Solve Global Antimicrobial Resistance<\/p>\n
\u00a0<\/p>\n
Antimicrobial resistance (AMR) is accelerating at a pace that threatens to become one of the leading causes of human mortality worldwide in coming decades. At least five million people are currently affected by infections caused by antibiotic resistance. In countries with a high incidence of resistant bacteria, a small wound can cause life-threatening infection that can\u2019t be treated with traditional antibiotics.<\/p>\n
\u00a0<\/p>\n
Antimicrobial peptides are known for their ability to kill bacteria due to their positive electrostatic charge, which attracts the negatively charged infectious bacteria. This allows peptides to puncture bacterial membranes and destroy the cells. However, their fragility in biological environments has been a major challenge to developing peptides as a viable treatment\u2014naturally occurring enzymes in the body can destroy them within seconds.<\/p>\n
\u00a0<\/p>\n
<\/p>\n
Amferia\u2019s management team – My Nyblom, Saba Atefyekta, Edvin Blomstrand, Rojan Modaresi, Daniel Hagberg, and Anand Rajasekharan, Photo: Saba Atefyekta <\/p>\n
(Not Pictured above: Maya Awada, Peter Andersson, Therese Rydell, Ingvar Karlsson, Ulrika Holmquist).\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Amferia\u2019s breakthrough is the development of a hydrogel platform, encasing the peptides in a solid protective gel. This design shields the vulnerable facets of peptides while allowing their bacteria-killing structures to remain exposed\u2014and lethal to even antibiotic-resistant bacteria. Amferia’s antimicrobial hydrogel kills bacteria without harming surrounding body tissue.<\/p>\n
\u201cThe hydrogel technology we\u2019ve developed enables the safe and stable use of antimicrobial peptides\u2014one of nature\u2019s most powerful defenses\u2014while preventing the enzyme degradation that has historically limited their use,\u201d Rajasekharan said.<\/p>\n
\u00a0<\/p>\n
Research shows that combining Amferia\u2019s hydrogel with antibiotics can dramatically amplify their bactericidal effect\u2014up to 64 times stronger\u2014demonstrating its potential to reshape infection management.<\/p>\n
\u00a0<\/p>\n
A Platform for Multiple New Product Lines<\/p>\n
\u00a0<\/p>\n
The capital infusion allows Amferia to continue to develop products applying the peptide-hydrogel technology across a broad range of clinical and veterinary use cases, including:<\/p>\n
\tDry-to-low exuding wound dressings
\n\tPost-operative and chronic wound care
\n\tTrauma and burn applications
\n\tSurgical materials
\n\tAntimicrobial coatings for implants and medical devices<\/p>\n
\u00a0<\/p>\n
The company continues to expand its veterinary presence in Europe with the BactiDefend\u2122 dressing and is advancing human-health pipeline products built on the same underlying platform.<\/p>\n
\u00a0<\/p>\n
Looking Ahead<\/p>\n
Amferia continues to expand its product pipeline, invest in research, and collaborate with global partners to redefine how infections are prevented and managed. By stabilizing one of nature\u2019s most effective bacterial defenses, the company offers a transformative platform with the potential to strengthen antibiotic treatments and improve outcomes across healthcare.<\/p>\n
\u00a0<\/p>\n
Learn more about Amferia<\/p>\n
https:\/\/www.amferia.com\/<\/a><\/p>\n https:\/\/news.cision.com\/amferia-ab\/r\/new-study-finds-innovative-peptide-hydrogel-restores-the-effectiveness-of-antibiotics-against-drug-r,c4067581<\/a><\/p>\n